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1. Introduction
Cardiomyopathies can be defined as disorders of the myocardium which are associated with
cardiac dysfunction and are aggravated by arrhythmias, heart failure and sudden death
[Ricardson, 2006]. Genetics has played a very important role in the understanding of the
different cardiomyopathies since, in 1957, Bridgen cited for the first time the word “cardio‐
myopathy” and in 1958, Teare, the British pathologist reported nine cases of septum hyper‐
trophy (Teare, 1958).
The American Heart Association (AHA) has classified cardiomyopathies as primary cardio‐
myopathies (the heart is the only organ affected) and secondary cardiomyopathies (the heart
is affected as part of a systemic disease). The European Society of Cardiology (ESC) has
classified them according to morphological and functional phenotypes involving their
pathophysiology (Maron, 2006; Maron, 2008; Elliott, 2008)
Primary cardiomyopathies are those which and can be genetic, nongenetic or acquired.
Secondary cardiomyopathies are those in which the cardiomyopathy is found in a systemic
disease. Primary cardiomyopathies can then be classified according to their anatomical and
functional impairment in hypertrophic cardiomyopathy, dilated cardiomyopathy (DCM),
restrictive cardiomyopathy (RCM), arrhythmogenic right ventricular cardiomyopathy/
dysplasia (ARVC/D), ion channel disorders. Secondary cardiomyopathies are those found in
muscular dystrophies, mitochondrial disorders among others. The unclassified cardiomyo‐
pathies are non-compaction cardiomyopathy and takotsubo cardiomyopathy (Elliott, 2008; )
The genetic diagnosis has a close involvement in the management of primary and secondary
cardiomyopathies and its development will have a key role in the understanding of the
different molecular mechanisms that lead to a cardiomyopathy.
© 2013 Vernengo et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
2. Hypertrophic cardiomyopathy
Hypertrophic cardiomyopathy (HCM) is a familial disease that in fifty percent of the cases is
inherited in an autosomal dominant pattern. The disorder shows complete penetrance in most
families although it depends on the age and the sex of the patients (Nimura, 1998, Richard,
2003, Richard, 2006).
As the prevalence of HCM is 1: 500, it can be stated that HCM is undoubtedly the most common
cardiovascular disorder (Maron, 2002).
HCM has been traditionally described as an unexplained hypertrophy of the left ventricle that
develops in the absence of systemic hypertension, valvular heart disease or amyloidosis. The
left ventricular hypertrophy (LVH) is usually asymmetric and involves the septum.
The clinical presentation is variable. There can be varying degrees of clinical severity which
can range from dyspnea, palpitations, atrial fibrillation, and syncopal episodes to congestive
heart failure and sudden death. Many can be asymptomatic throughout their whole life,
whereas others may even require heart transplantation. It is the most common cause of death
in young athletes while practicing sports.
HCM generally has normal systolic function, impaired diastolic function and outflow ob‐
struction in about 25%. The histopathology shows myocyte disarray, interstitial fibrosis and
hypertrophy (Richard, 2006, Ho, 2007).
Mutations in any of the thirteen sarcomeric genes lead to HCM. (See Table 1). The sarcomere
has a complex structure where the proteins that form it interact among themselves. The
different mechanisms that cause HCM are not yet completely understood. Most mutations in
HCM are private of each family and there is clinical heterogeneity within family members
(Richard, 2006 Hayashi, 2004; Frank, 2011).
3. Dilated cardiomyopathy
Dilated cardiomyopathy is the most common cause of congestive heart failure in young
patients. The prevalence is ~36: 100,000 in the U.S. It is characterized by ventricular chamber
enlargement, thin wall thickness, impaired left ventricular systolic function, and there is also,
in some cases, secondary diastolic dysfunction. The most common feature is congestive heart
failure, though, conduction impairment, syncope and sudden death may also occur. It is an
important cause of cardiac transplantation (Sugrue, 1992).
The histological findings are nonspecific and they include myocyte loss and interstitial fibrosis.
Familial cases of DCM were initially considered to be quite rare. However, careful screenings
have shown that up to 35% of the probands´ relatives have a DCM familial disorder.
In these families, the pattern of inheritance is variable, so the patients present both locus
heterogeneity and allellic heterogeneity. Mutations in many genes have been reported to cause
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different forms of dilated cardiomyopathy. Therefore, autosomal dominant, autosomal
recessive, and X-linked inheritance can be observed. (See Table 2) However, the autosomal
dominant pattern is the most frequent mode of inheritance. It has been demonstrated that DCM
has reduced penetrance. The age of onset shows great variability though it is usually appears
in adulthood (Mangin, 1999). When the mutation is in one of the sarcomeric genes the affected
patients are usually young adults (Aernout Somsen, 2012).
HCM gene Symbol Locus name Chromosome locus Protein
Beta-myosin heavy chain MYH7 CMH1 14q2 Myosin heavy chain,
cardiac muscle beta
isoform
Myosin-binding
protein C
MYBPC3 CMH4 11p11.2 Myosin-binding protein C,
cardiac-type
Troponin T TNNT2 CMH2 1q32 TroponinT, cardiac muscle
Troponin I TNNI3 CMH7 19q13.4 TroponinI, cardiac muscle
Alpha-tropomyosin TPM1 CMH3 15q22.1 Tropomyosin1 alpha chain
Regulatory myosin light chain MYL2 CMH10 12q24.3 Myosin regulatory light
chain 2, ventricular/
cardiac muscle isoform
Essential myosin
light chain
MYL3 CMH8 3p21 5 Myosin light polypeptide 3
Actin ACTC1 CMH11 15q14 Actin, alpha cardiac
muscle 1
Cardiac troponin C TNNC1 CMH13 3p21.1 Troponin C, slow skeletal
and cardiac muscles
Titin TTN CMH9 2q24.3 2 Titin
Alpha-myosin
heavy chain
MYH6 CMH14 14q12 Myosin heavy chain,
cardiac muscle alpha
isoform
Muscle LIM
protein
CSRP3 CMH12 11p15. Cysteine and glycine-rich
protein 3, muscle LIM
protein
Telethonin TCAP CMH11 17q12 1 Telethonin
Table 1. Sarcomeric genes that cause HCM
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DCM gene Symbol Locus name Chromosome locus Protein Mode of
inheritance
Lamin A/C gene LMNA CMD1A 1q21 lamin A and lamin C AD
LDB3 gene CMD1C 10q22-q23 LIM domain-binding
protein 3
AD
TNNT2 gene TNNT2 CMD1D 1q32 Troponin T, cardiac
muscle
AD
SCN5A CMD1E 3p Sodium channel protein
type 5 subunit alpha
AD
TTN gene TTN CMD1G 2q31 Titin AD
DES gene DES CMD1I 2q35 Desmin AD
EYA4 gene EYA4 CMD1J 6q23-q24 Eyes absent homolog 4 AD
SGCD gene SGCD CMD1L 5q33 Delta-sarcoglycan AD
CSRP3 gene CSRP3 CMD1M 11p15.1 Cysteine and glycine-rich
protein 3
AD
TCAP gene TCAP CMD1N 17q12; Telethonin AD
ABCC9 gene CMD1O, on 12p12.1; ATP-binding cassette,
subfamily C, member 9
AD
PLN gene PLN CMD1P on 6q22.1;, Cardiac phospholamban AD
ACTC1 gene ACTC1 CMD1R 15q14 Actin, alpha cardiac
muscle 1
AD
MYH7 gene MYH7 CMD1S 14q12; Myosin 7 AD
TMPO gene TMPO CMD1T 12q22 Hymopoietin AD
PSEN1 gene PSEN1 CMD1U 14q24.3 Presenilin-1 AD
PSEN2 gene PSEN2 CMD1V 1q31-q42; Presenilin-2 AD
metavinculin VCL CMD1W 10q22-q23 metavinculin VCL AD
fukutin FKTN CMD1X 9q31 Fukutin AD
TPM1 gene Fukutin CMD1Y 15q22.1 tropomyosin-1 AD
TNNC1 gene TNNC1 CMD1Z 3p21.3-p14.3 slow troponin-C AD
ACTN2 gene ACTN2 CMD1AA 1q42-q43; Alpha-actinin-2 AD
DSG2 gene DSG2 CMD1BB 18q12.1-q12.2; desmoglein-2 AD
NEXN gene NEXN CMD1CC 1p31.1 Nelin AD
RBM20 gene RBM20 CMD1DD 10q25.2; RNA-Binding motif
protein 20
AD
MYH6 gene MYH6 CMD1EE 14q12 Myosin 7 AD
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DCM gene Symbol Locus name Chromosome locus Protein Mode of
inheritance
TNNI3 gene TNNI3 CMD1FF 19q13.4; Troponin I, AD
SDHA gene SDHA CMD1GG 5p15; Succinate dehydrogenase
complex subunit A
AD
BAG3 gene BAG3 CMD1HH 10q25.2-q26.2 BCL2-associated
athanogene 3
AD
TNNI3 gene TNNI3 CMD2A, 19q13.42 Troponin I, cardiac
muscle
AR
GATAD1 gene. GATAD1 CMD2 7q21.2 GATA zinc finger domain
containing protein 1
AR
Dystrophin gene DMD CMD3B Xp21.2 dystrophin X-linked
LAMP2 gene LAMP2 Danon disease Xq24 lysosome-associated
membrane protein-2
X-linked
TAZ gene TAZ Xq28 dystrophin X-linked
Table 2. Genes tha cause DCM
Mutations on the following genes CMD1B on 9q13; CMD1H on 2q14-q22; CMD1K on 6q12-
q16; and CMD1Q on 7q22.3-q31.1 can also cause DCM.
4. Restrictive cardiomyopathy
Familial restrictive cardiomyopathy (RCM) is a rare disease which is inherited in autosomal
dominant pattern with incomplete penetrance (Katritsis 1991). The exact prevalence of RCM
is unknown (Elliott, 2008). In childhood, RCM accounts for 2–5% of cardiomyopathies and has
a grave prognosis (Kaski, 2008.)
RCM is characterized by abnornal diastolic function, which has a restrictive filling pattern, a
reduced diastolic volume of one of the ventricles or both ventricles, enlargement of the atria,
pulmonary hypertension and heart failure. In the early stages of the disorder the systolic
function may be normal, but as the disease progresses, the systolic function generally declines
(Kushwaha, 1997).
The familial RCM is linked to the cardiac troponin genes. RCM1 is caused by a mutation in the
TNNI3 gene on chromosome 19q13. This gene encodes the cardiac muscle isoform of troponin
1. RCM2 has been mapped to chromosome 10q23. RCM3 is caused by mutation in the TNNT2
gene. Mutations in the sarcomere gene, alpha-cardiac actin gene (ACTC) have also been
reported to cause RCM,
In many cases RCM can be observed overlapping with either HCM or DCM. (Kamisago,
2000; Olson, 2002; Zang, 2005; Kaski, 2008).
The Role of Genetics in Cardiomyopathy
http://dx.doi.org/10.5772/55775
111
5. Arrhythmogenic right ventricular cardiomyopathy / dysplasia
Arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/ARVD) is a commonly
inherited disorder with a family history in 30 to 50% of the cases (Klauke, 2010).
The prevalence has been estimated 1:2000 to 1:5000 in the general population (Peters 2006,
Cox&Hauer, 2011).
ARVC is characterized by fibro-fatty replacement of the myocardium with a marked involve‐
ment of the right ventricle. ARVC can be defined by the presence either sectored or global right
ventricular dysfunction. The left ventricular abnormalities which lead to DCM may take place
later. Clinical features include tachyarrhythmias, electrocardiographic abnormalities, systolic
heart failure, syncope and sudden death. ARVC is a frequent cause of sudden death in young
people and athletes (Maron, 2006).
It is transmitted with an autosomal dominant pattern, though autosomal recessive families
have also been reported. Incomplete penetrance and great variability in the symptoms have
been observed (Hamid, 2002; Awad, 2008; Eliott, 2008; Klauke, 2010, Cox&Hauer, 2011).
Desmosomes are intercellular junctions that link intermediate filaments to the plasma
membrane and are essential to tissues that experience mechanical stress such as the myocar‐
dium. Mutations in the cardiac desmosome genes are to be held responsible for most of the
cases that cause the disorder. (See Table 3)
The mutations p.S13F, p.E114del and p.N116S in the desmin gene have the same ARVC cardiac
phenotype. In transfection cells aggresome formation in the cytoplasm was observed (Van
Titelen, 2007; Vernengo, 2010; Klauke, 2010). Only recently has it been proven that seven
members of the Swedish family with ARVC7 had the p.Pro419Ser mutation in DES, instead of
a mutation linked to chromosome 10q23.2 (Melberg, 1999; Hedberg, 2012).
Naxos disease and Carvajal disease are ARVC inherited in an autosomal recessive pattern. The
former is caused by mutations in the plakoglobin gene on chromosome 17q21,2 and the latter
by mutations in the desmoplakin gene on chromosome 6p24 (Protonotarios, 1986; McKoy,
2000; Schonberger, 2001; Cox&Hauer, 2011).
6. Non–compaction cardiomyopathy
Non-compaction cardiomyopathy (NCCM) has been classified as a primary cardiomyopathy
with a genetic etiology.The age of onset varies from neonatal to adult hood. There is variability
in the clinical features which include heart failure, arrhythmias and thromboembolism, but
patients can also be asymptomatic]. The most common congenital heart defects in NCCM are
Ebstein’s anomaly, septal defects and patent ductus arteriosus,
The patients have a thickened two-layered myocardium with a thin, compact, epicardial layer
and a severely thickened endocardial layer with a ‘spongy’ appearance due to prominent
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trabeculations and intertrabecular recesses (Hermida-Prieto, 2004; Freedom, 2005; Budde,
2007; Monserrat, 2007; Klaassen, 2008)
The majority of the patients have an autosomal dominant mode of inheritance.
Mutations in several genes coding for sarcomeric proteins have been described in NCCM, such
as β-myosin heavy chain (MYH7), cardiac myosin-binding protein C (MYBPC3), α-cardiac
actin (ACTC1), cardiac troponin T (TNNT2), α-tropomyosin (TPM1) and cardiac troponin I
(TNNI3). MYH7 has been reported to be the most frequent disease gene in NCCM in the
absence of HCM (Ichida, 2001; Hermida-Prieto. 2004; Vatta, 2003; Shan, 2008).
7. Takotsubo cardiomyopathy
Takotsubo cardiomyopathy is characterized by an acute but transitient LV systolic dysfunction
without atherosclerotic coronary artery disease and it is triggered by psychological stress
(Sharkey, 2005; Sealove, 2008).
8. Ion channel disorders
The cell membrane transit of sodium and potassium ions is ruled by the ion channel genes
which encode proteins responsible for the right transit of these ions. Mutations in these
ARCV gene Symbol Locus name Chromosome locus Protein
Transforming growth factor
beta- 3
TGFB3 ARVD1 14q2 Transforming growth factor
beta-3
Ryanodine receptor 2 RYR2 ARVD2 1q43 RYR2
Unknown Unknown ARVD3 14q12-q22 Unknown
Unknown Unknown ARVD4 2q32 .1-q32.3 Unknown
transmembrane protein 43 TMEM43 ARVD5 3p25 .1 Transmembrane protein 43
Unknown Unknown ARVD6 10p14-p12 Unknownn
Desmin DES ARVD7 2q35 Desmin
Desmoplakin DSP ARVD8 6p24 .3 Desmoplakin
Plakophilin-2 PKP2 ARVD9 12p11 .21 Plakophilin-2
Desmoglein-2 DSG2 ARVD10 18q12 .1 Desmoglein-2
Desmocollin-2 DSC2 ARVD11 18q12 .1 Desmocollin-2
Junction plakoglobin JUP ARVD12 17q21 .2 Junction plakoglobin
Desmin DES ARVC 2q35 Desmin
Table 3. Genes that cause ARVC.
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proteins lead to a group of familial disorders (Aleong, 2007). These ion channel disorders
include the Romano-Ward syndrome (long QT syndromes), the short-QT syndrome (SQTS),
Brugada syndrome, and the catecholaminergic polymorphic ventricular tachycardia (CPVT).
5% to 10% of the sudden deaths in children can be associated to ion channel disorders (Modell
& Lehmann, 2006).
The clinical diagnosis of the ion channelopathies can be often made by identification of
alterations found on the ECG (Aleong, 2007; Kass, 2005).
8.1. Romano–Ward syndrome
RWS may be sporadic or transmitted as an autosomal-dominant trait with reduced penetrance.
It is the most common form of inherited long QT syndrome. The prevalence of RWS has been
estimated to be 1:3000 to 1:7000.
The Romano-Ward syndrome (RWS) is tipically identified in patients that present syncope,
seizures, or sudden death due to episodic taquiarrhythmias, QT prolongation and T-wave
abnormalities, interval torsade de pointes that lead to ventricular fibrillation and death.
RWS is associated with mutations in the following genes: KCNQ1 on chromosome 11p15.5-
p15.4, KCNE1 on chromosome 21q22.12, KCNE2 on chromosome 21q22.11, KCNH2 on
chromosome 7q36.1, SCN5A on chromosome 3p22.2, CAV3 on chromosome 3p25.3, SCN4B on
chromosome 11q23.3, AKAP9 on chromosome 7q21.2, SNTA1 on chromosome 20q11.21 and
KCNJ5 on chromosome 11q24.3 (Schwartz 1993; Schwartz 2001: Schwartz 2011).
8.2. Jervell and Lange–Nielsen syndrome
The Jervell and Lange-Nielsen syndrome (JLNS) is inherited as an autosomal recessive trait.
The affected children present symptoms before the age of three and they died before the age
of 15 if they are not treated.
The prevalence can vary considerably and it depends on the population studied.
The patients have a more severe QT prolongation (greater than 500 msec) which is associated
which tachiarrhythmias including torsade de pointes, ventricular fibrillation, syncope and
sudden death.
Mutations in the KCNQ1 gene on chromosome 11p15.5-p15.4, KCNE1 gene on chromosome
21q22.12, have been reported in the affected individuals (Schwartz 2000; Schwartz 2006).
8.3. Timothy syndrome
Timothy syndrome is a rare autosomal dominant disorder are due to either a de novo mutation
or parent germline mosaicism Mutations in the same gene CACNA1C cause the two forms of
the disorder: the classic, type 1, and type 2. The reported cases of the patients suffering type 1
syndrome have shown complete penetrance (Splawski, 2004).
This complex multisystem disorder has a long QT syndrome associated with syndactily.
Various forms of congenital heart defects such as tetralogy of Fallot, hypertrophic cardiomy‐
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opathy have been observed. The type 2 patients that have been reported did not have syn‐
dactily (Splawski, 2005)
Children died at age of 2.5 years due to ventricular tachycardia and ventricular fibrillation,
infection or hypoglycemia (Reichenbach, 1992; Marks, 1995a; Marks 1995b; Splawski 2004; Lo-
A-Njoe, 2005).
8.4. Brugada syndrome
The Brugada syndrome, which is inherited in an autosomal dominant pattern, is associated
with sudden death in young people as the patients have malignant ventricular tachyarrhyth‐
mias and sudden cardiac death. The heart is not affected by either a structural heart or systemic
disease.
The age of appearance ranges from a two- day- old patient to 85 years (Marks, 1995a; Marks,
1995b; Splawski, 2004; Huang, 2004; Lo-A-Njoe, 2005).
The cardiac differential diagnosis must be made with Duchenne muscular dystrophy, Frie‐
dreich ataxia and ARVC.
8.5. Catecholaminergic polymorphic ventricular tachycardia
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited tachyarrhyth‐
mia that is caused by acute adrenergic activation during exercise or acute emotion in young
adolescents.
The age of onset varies from 7-9 years to the fourth decade of life.
It presents locus heterogeneity and in only approximatedly 50% of the cases the mutations in
the genes causing the disease have been identified.
The prevalence of CPVT in the population is not known, but it could be estimated in approx‐
imately 1:10,000.
There is an autosomal dominant form caused by mutations in the RYR2 gene that encodes the
ryanodine receptor 2, a calcium-release channel (George, 2003).
The autosomal recessive form is due to mutations in the calsequestrin 2 gene on chromosome
1p13.1 (Wilde, 2008).
8.6. Short–QT syndrome
Short-QT syndrome is a familial disease that is characterized by a high incidence of sudden
death. Patients with this disease have QT intervals that are <300 ms, and increased risk of atrial
and ventricular arrhythmia.
It is an autosomal dominant inherited disorder that affects patients of 30 years of age, but the
fibrillation can even be observed in newborns and young patients.
The Role of Genetics in Cardiomyopathy
http://dx.doi.org/10.5772/55775
115
Missense mutations in the KCNH2 gene on chromosome 7q36.1, in the KCNQ1 gene on
chromosome 11p15.5-p15.and the KCNJ2 gene on chromosome 17q24.3 have shown that this
is a genetically heterogeneous disease.
9. Cardiomyopathy in muscular dystrophies
Muscular dystrophies are a heterogeneous group of inherited disorders, characterized by
progressive weakness and wasting of the skeletal muscles. They are generally associated with
cardiomyopathy. In many cases, there is no correlation between the skeletal myopathy and
the involvement of the heart. The mutations of the genes that cause muscular dystrophies affect
the skeletal and/or cardiac muscles. These include proteins which are associated with the
dystrophin–glycoprotein complex, the nuclear lamina or the sarcomere (Hermans, 2012).
Cardiomyopathy occurs in myofibrillar myopathy, myotonic dystrophies, myotonic myopa‐
thies, dystrophinopathies, Emery-Dreifuss muscular dystrophy, and limb girdle muscular
dystrophies (Hermans, 2012).
They are inherited in autosomal dominant, autosomal recessive and X-linked mode. (See Table
4, Table 5).
The different forms of muscular dystrophies vary in the age of onset with no male or female
prevalence and have different clinical features and severity. Mutations in the genes that are
involved muscular dystrophies can cause hypertrophic, dilated or restrictive cardiomyopathy,
but most cardiomyopathies in patients with a muscular dystrophy are of the dilated type. The
progression of the disorders and life expectancy vary widely, even among different members
of the same family. Patients die of sudden death due to conduction defects, and heart failure.
In dystrophinopathies, sarcoglycanopathies, and the disorders that are linked to mutations in
the fukutin-related protein, the feature that stands out is the cardiomyopathy the patients
suffer. In muscular dystrophies, the patients usually have a dilated cardiomyopathy. Hyper‐
trophic cardiomyopathy can be observed in Danon disease, α-B crystallinopathy, and on
patients or carriers of DMD and BMD. (De Ambroggi, 1995, Vicart 1998; Nguyen, 1998;
Lazarus, 1999; Melacini, 1999; Barresi, 2000; Politano, 2001; Selcen, 2003; Fanin, 2001; Jefferies,
2005; Nakanishi, 2006; Connuck, 2008; Kaspar, 2009; Goldfarb, 2009; Lilienbaum, 2012;
Hermans, 2012)
10. Mitochondrial disorders
Mitochondrial disorders are a heterogeneous group of disorders that have common clinical
features and are caused by the different mutations found in either the nuclear or mitochondrial
DNA (mtDNA) genes which regulate the mitochondrial respiratory chain, the essential final
common pathway of aerobic metabolism, tissues and organs. mtDNA is maternally inherited
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and the disorders can appear at any age. All the mitochondria have multiple copies of their
own mtDNA and the mutation rate is much higher than in nuclear DNA (Walter, 2000;
Carrasco, 2005; De Jonge, 2011).
Many mitochondrial disorders involve multiple organ systems such as the brain, the heart, the
liver, and the skeletal muscles which are, therefore, affected due to the fact they depend on the
energy and they are especially susceptible to energy metabolism impairment (Walter, 2000;
Carrasco, 2005; De Jonge, 2011).
Mitochondrial dysfunction and clinical symptoms appear when the heteroplasmic levels are
above 80%-90% (Walter, 2000; Carrasco, 2005; De Jonge, 2011).
Disease Name Gene Symbol Locus
name
Chromosome
locus
Protein Mode of
inheritance
Desminopathy Desmin DES MFM1 2q35 Desmin AD/AR
Alpha-B
crystallinopathy
CRYAB geneCRYAB MFM2 11q23.1 alpha-B-crystallin AR/AD
Myotilinopathy Myotilin MYOT
(TTID)
MFM3 5q31.2 Myotilin
(titinmmunoglobuli
n domain protein)
AD
ZASPopathy ZASP LDB3 MFM4 10q23.2 LIM domain-binding
protein 3
AD
Filaminopathy FilaminC FLNC MFM5 7q32.1 Filamin C AD
BAG3-Related
Myofibrillar
Myopathy
BCL2-
associated
athanogen 3
BAG3 BAG3 10q26.11 BAG family
molecular
chaperone
regulator 3
AD
Myotonic dystrophy
type 1
myotonin-
protein
kinase (Mt-
PK).
DMPK DMPK 19q13.3 dystrophia
myotonica-protein
kinase
AD
Myotonic dystrophy
type 2
zinc finger
protein-9
gene
CNBP 3q21.3 zinc finger protein-9AD
Duchenne/Becker
muscular dystrophy
dystrophin DMD DMD Xp21.2 dystrophin X-linked
Emery-Dreyfuss
Muscular
Dystrophy1,X-linked
EMD gene EMD EMD1 Xq28 emerin X-linked
Table 4. Genes that cause cardiomyopathy in muscular dystropies
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The different mitochondrial cardiomyopathies are a result of the heart being commonly
affected. Sometimes, the cardiomyopathy is diagnosed during the first year of life even before
the mitochondrial disorder has been diagnosed. Both hypertrophic and dilated cardiomyopa‐
thies have been reported (Holmgren, 2003, de Jonge, 2011).
11. Kearns-Sayre syndrome
The Kearns-Sayre syndrome (KSS) is characterized by the triad: onset of the disorder before
the age of 20, progressive external ophthalmoplegia and pigmentary retinopathy. A cerebro‐
spinal fluid protein concentration greater than 100 mg/d, and a commonly elevated lactate and
pyruvate concentrations in blood and cerebrospinal fluid are found.
The KSS has cardiac involvement with conduction defects such as right bundle branch block,
left anterior hemiblock or complete A-V block. These patients can develop a cardiomyopathy
usually dilated (Roberts, 1979; Anan, 1995; Carrasco, 2005).
11.1. MELAS
It is a multisystem disorder with onset in childhood with mitochondrial encephalomyopathy,
lactic acidosis, and recurrent stroke-like episodes. The variability of symptoms and the severity
of the syndrome make it difficult to confirm the diagnosis. MELAS is transmitted by maternal
inheritance.
Disease Name Gene Symbol Locus name Chromosome
locus
Protein Mode of
inheritance
LGMD2C gamma
sarcoglycan
gene
SGCG SGCG 13q12-q13 gamma
sarcoglycan
AR
LGMD2D alpha
sarcoglycan
gene
SGCA SGCA 17q21 Alpha
sarcoglycan
AR
LGMD2E Beta
sarcoglycan
gene
SGCB SGCB 4q12 Beta
sarcoglycan
AR
LGMD2F Delta
sarcoglycan
gene
SGCD SGCD 5q33-q34 Delta
sarcoglycan
AR
LGMD2I fukutin related
protein gene
FKRP FKRP 19q13.32 fukutin related
protein
AR
Table 5. Limb-girdle muscular dystrophies
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The cardiac involvement is considered to be 18–100% (Hirano, 1994; Vydt, 2007; Wortmann,
2007). The first symptom the affected children have is the cardiomyopathy. The most common
feature is a hypertrophic cardiomyopathy, although dilation has also been reported (Okajima,
1998).
Mutations in the nuclear genes that also encode mitochondrial proteins can cause cardiomyo‐
pathies. These disorders are sometimes not considered among the group of mitochondrial
primary disorders. Two of the most well known disorders are Friedreich´s ataxia and Barth
syndrome (de Jonge, 2011).
Friedreich´s ataxia is an autosomal recessive disorder. Frataxin, the protein encoded by FXN,
is involved in the mitochondrial transport and is needed for the synthesis of the enzymes of
the respiratory chain complexes I – III and aconitase. When the protein is mutated in Friederich
´s ataxia, it does not allow the correct respiratory function.
Barth syndrome is a recessive X-linked inherited disease chacterized by cardiomyopathy and
neutropenia. The cardiac disease presents a dilated cardiomyopathy, often with a degree of
left myocardial thickening and, sometimes, endocardial fibroelastosis. The cardiac disease
appears at birth or in the first few months of life
Mutations in the tafazzin gene are to be held responsible for this disorder because of the
inhibition of this pathway leads to changes in mitochondrial architecture and function
(Spencer, 2006, Schamme, 2006).
12. The impact of genetics in the understanding of cardiomyopathy
Although the diagnosis is based primarily on DNA analysis, a thorough clinical history and
examination, blood tests, the ECG, echocardiography, electromyography, and muscle biopsy
can also provide information that can be helpful for the diagnosis not only of the patients, but
also of the asymptomatic carriers.
With the expansion in number of the different disorders that have myocardial involvement in
conjunction with the development of their molecular and biochemical bases, it can be stated
that these will play a most important role in the understanding of the pathophysiology of the
syndromes.
The exact role and function each mutated protein has and the pathogenic mechanisms that
lead to the different disorders still have to be elucidated, in spite of the fact that the mutations
that cause them have been found.
It has also been observed that the mutations within the same gene and in the same family can
give rise to distinct phenotypes in HCM, DCM and RCM. The pathogenesis of the three major
types of cardiomyopathy can be linked to the the genetic mutations in the different sarcomeric
proteins. These gene mutations are responsible to trigger the different pathways that lead to
the remodeling of the heart. The mechanisms why this occurs are still unclear and the animal
models are markedly distinct.
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Since HCM is an autosomal dominant disorder most of the patients suffering from it are
heterozygous. Mutations in MYH7 and/or MYBPC3 genes account for 80% of the mutations
(Richard, 2006).
In some cases, patients have two different mutations, usually in MYH7 and/or MYBPC3 genes.
These mutations result in the patients being compound heterozygous. The double heterozy‐
gotes that have also been observed have mutations in the MyBP-C/ β –MHC, MyBP-C/
TNNT2, MyBP-C/TNNT3, MyBP-C/TPM, β-MHC/TNNT2 genes. Sometimes, the patients can
be homozygous for a mutation in the genes MyBP-C, β -MHC, and TNNT2 (Richard, 1999;
Richard 2003; Van Driest, 2004; Ingles, 2005; Richard 2006).
The genotype-phenotype correlations have been linked to specific mutations (Richard, 2006).
The different mutations in the MYH7gene show great variability in symptomatology. Patients
with the R403Q, R719W and R719Q mutations have complete penetrance, severe hypertrophy
and short life expectancy, whereas those with the V606M mutation have a mild progression
(Ho, 2000; Richard, 2006; Overeem, 2007; Uro-Coste, 2009).
All the patients that have mutations in the TNNT2 gene seem to have a more severe course. In
most cases, the affected patients carrying the mutations R92W, R92Q, I79N are young, and
even though they have a mild LVH, they died of sudden death. The F110I mutation does not
seem to have a so severe development as the rest of the mutations in this gene (Watkins,
1995; Arian, 1998; Tardiff, 2005, Richard, 2006).
It is believed that patients having double mutations have a greater severity of the disorder due
to a double dose effect (Ingles, 2005).
Incomplete or reduced penetrance has been observed in many cases (20 to 30%) as there are
parents that are carriers of the mutations, but they have not developed the disease. It is
unknown whether carriers will develop the disorder at a certain age of their lives or will remain
asymptomatic. Symptoms show a great variability among the patients that have the same
mutation and suffer the disorder. These may be due to gene interaction, environmental factors
and modifier genes (Michels, 1992; Mestroni, 1999; Criley, 2003; Richard, 2006).
In many cases RCM can be observed overlapping with either HCM or DCM. An autosomal
dominant cardiomyopathy has been described where the single sarcomere TNNT2 gene
mutation can cause idiopathic RCM in some patients, or HCM or DCM in others.
All affected members of a RCM-associated family have the I79N mutation in the TNNT2 gene,
thus showing the variability of the disorders (Peddy, 2006; Menon, 2008).
It is very difficult to assess the genotype-phenotype correlation in NCCM. It seems that when
there are mutations in the alpha-dystrobrevin gene (DTNA) on chromosome 18q12.1 and
taffazin gene (TAZ) on chromosome Xq28 (Bleyt, 1997). It has been observed that when the
mutations are in a sarcomeric gene, they give rise to a truncated protein and the onset of the
disorder is during childhood. When there is an adult onset, there can be multiple mutations
in a non sarcomeric gene thus the phenotype is more severe
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As soon as the patients are diagnosed with the myopathies mentioned above they should be
cardiologically checked-up, and should be treated immediately as the cardiac therapy
improves the cardiac involvement and life expectancy
In Timothy syndrome the molecular diagnosis of CACNA1C should be performed in several
tissues, including sperm.
It has been observed that mutations in the lamin A/C gene cause CMD1A, LGMD1B or EDMD2
in the same family (Becane, 2000; Brodsky, 2000)
The mitochondrial deletion syndromes are generally not inherited. The de novo deletions that
take place in the mother's oocytes during germline development or in the embryo during
embryogenesis are to be held responsible for these syndromes. 90% of the patients with KSS
have deletions of mtDNA. The deletions are present in all tissues in individuals with KSS.
There is no correlation between the size or the location of the mtDNA deletion and the
phenotype and penetrance because there are related to the mutation load.
It has suggested that the mutations in the nuclear gene RRM2B gene cause cause KSS following
a Mendelian mode of inheritance. The patient had multiple mtDNA deletions and a normal
left ventricular function with an increased thickness of the interventricular septum and left
posterior ventricular wall (Pitceathly, 2012).
Approximately 80% of cases of MELAS are due to mutations in the mtDNA gene MT-TL1
which encodes tRNA leucine. The mutations in MT-ND5 gene which encodes the NADH-
ubiquinone oxidoreductase subunit 5 have also been found in individuals with MELAS or with
overlap syndromes (Di Mauro,2005).
13. What should the genetic counseling be in cardiomyopathy?
To provide genetic counseling to an individual that has a cardiomyopathy is not an easy task.
When a patient or a relative that has been diagnosed with cardiomyopathy comes for genetic
counseling, the geneticist has to be forthright and explain that there are all sorts of disorders
that cause it, locus heterogeneity and clinical variability.
It is very important that when a numerical value is provided the patient and/or his family
understand what has been explained to them. It is necessary to be very clear that chance does
not have a memory. It would be embarrassing to face a family that comes with a second affected
child because they have misinterpreted the information provided to them.
It should also be pointed out that the molecular diagnosis of a disorder it is not only time
consuming and a very expensive process, but also that, sometimes, there is not a specific
mutation that stands out in the different disorders that cause a cardiomyopathy. Many patients
do not have an identified causing gene defect.
Opinions differ about procedures when consultants are under 18 and asymptomatic, and at
risk of having the disorder when adults, and there is not a causal treatment. Therefore, running
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the molecular test of the disorder would be inappropriate. If a mutation is found, the children
will not longer lead a normal life and it will also have a negative effect on family life.
In HCM, the first step the geneticist should take is to order the molecular analyses of MYH7
and MYBPC3, the two genes that carry most of the mutations.
Should the mutations not be in these two genes, the genetic analyses of TNNT2, TNNT3, MYL2,
MYL3, TPM1 and ACTC might clarify other cases.
Sometimes, if no mutations are found in any of the genes tested, the disorder cannot be ruled
out because it is likely that a new gene not yet discovered can be the cause.
In DCM the mode of inheritance has to be defined in other to provide a correct counseling as
the there is locus and allelic heterogeneity.
In the autosomal dominant cardiomyopathies most individuals diagnosed have an affected
parent. However, the index case may have the disorder as the result of a de novo mutation.
In HCM, it is not known the number of cases that are caused by these de novo gene mutations.
While in Brugada syndrome and in RWS de novo mutations are low, and in CPVT is almost 40%.
Timothy syndrome is due to either a de novo mutation or parental germline mosaicism. They
do not live long enough to reproduce.
Only the siblings are at risk of inheriting the disorder.
When there is a de novo mutation, alternate paternity and maternity as well as whether the
patient is adopted have to be ruled out.
The offspring of a patient suffering autosomal dominant familial cardiomyopathy has a 50%
chance of inheriting the mutation. Families in which penetrance appears to be incomplete or
reduced have been observed; therefore a parent with a mutation that causes the disorder is not
affected whereas the son or daughter is. The severity and age of onset cannot be predicted.
The siblings of the index case depend on the genetic condition of their parents. If a parent is
affected or has the mutation that causes the disorder, the risk to inherit the mutated allele is 50%.
In the cases reported where more than one mutation in one the genes encoding a sarcomere
protein has been identified in a patient with HCM, it is very difficult to assess the mode of
inheritance and makes it arduous for the geneticist to give an accurate risk assessment to
another family member.
It is essential to provide patients and relatives that are at risk, the potential risk their offspring
might have in these disorders and the reproductive options they have.
In the autosomal recessive traits the parents are obligate carriers. The offspring of a patient
suffering an autosomal recessive familial cardiomyopathy will be obligate carriers. The
siblings have a 25% chance of inheriting the mutation.
The deletions in mtDNA are usually due to de novo mutations, so there is only one family
member affected. The offspring of a male patient are not at risk whereas all females´ offspring
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are at risk of inheriting the mutation. There is not risk that any other family member will inherit
the disease.
When there are multiple mtDNA deletions the analysis of RRM2B should be performed
because it conditions the genetic counseling.
A prenatal diagnosis for those patients there are at risk for any cardiomyopathy is possible, if
the mutation carried by the parents or the proband has been previously identified.
Preimplantation genetic diagnosis (PGD) may be available for families in which the mutation
that causes the disorder has already been identified.
14. Conclusion
In spite of the fact that there has been considerable improvement in the molecular diagnosis
of the different mutations that lead to cardiomyopathies, we still have to learn more about the
pathophysiology of these sometimes deadly disorders.
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